整合医学跨越儿科癌症护理轨迹:叙述性审查
相关实验视频
Updated: May 11, 2026

10:02
Whole-body PET/MRI of Pediatric Patients: The Details That Matter
Published on: December 19, 2017
14.6K
Eran Ben-Arye1,2, Noah Samuels3, Georg Seifert4
1Integrative Oncology Program, The Oncology Service, Zebulun Medical Centers, Clalit Health Services, Haifa and Western Galilee District, Carmel &, Lin, Israel. eranben@netvision.net.il.
Current oncology reports
|May 11, 2024
概括
儿科综合性瘤学 (IO) 提供基于证据的补充疗法,以支持患有癌症的儿童. 需要进行进一步的研究,以制定安全有效地与传统护理一起使用这些治疗方法的指导方针.
科学领域:
- 儿科瘤学 儿科瘤学
- 综合医学是一个整体的医学.
- 补充和替代医学 (CAM)
背景情况:
- 在儿科癌症患者及其护理人员中,CAM的使用很常见.
- 一些患者在未知儿科医生的情况下使用CAM,而另一些患者则寻求整合性瘤学 (IO) 咨询.
- IO将基于证据的补充疗法与传统护理相结合,以加强支持性和息性治疗.
研究的目的:
- 审查儿科综合性瘤学 (IO) 的现状.
- 探索IO护理模型的未来方向.
- 检查IO在儿科瘤学和血液瘤学中的作用.
主要方法:
- 这是一个叙事评论.
- 该审查审查了关于儿科IO模式的现有临床研究.
- 它评估了CAM在儿童癌症护理中的有效性和安全性.
主要成果:
- 临床研究支持了领先的儿科IO模式的有效性.
- 解决了与CAM使用相关的潜在安全问题.
- 越来越多的证据支持儿科IO模型的好处和实施.
结论:
- 需要进行进一步的研究,以制定儿科IO的临床指南.
- 准则应解决儿童瘤学中CAM的有效性和安全性.
- 医疗保健专业人员需要对IO服务有更好的理解和转诊指示.
相关概念视频
Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...

